Skip to main content
TipRanks
Go Ultimate75% OFF

Neovacs SA (ALNEV) AI Stock Analysis

5 Followers
FR:ALNEV

Neovacs SA

(Paris:ALNEV)

Select Model
Rating:41Neutral
Price Target:EUR 0.07▼(-4.41% Downside)
Action:reiterated
Date:11/14/26

Weak financial performance from persistent losses and cash burn is the dominant factor, further pressured by bearish technical indicators in this high-risk early-stage biotech.

Positive Factors
Low leverageVery low leverage gives Neovacs greater financial flexibility than a heavily indebted biotechnology company and reduces immediate refinancing pressure. While it does not resolve losses, the limited debt burden can preserve strategic options as management seeks partnerships, funding, or operational improvements.
Negative Factors
Persistent unprofitabilityPersistent losses show that Neovacs has not yet established an economically sustainable operating model. Negative profitability limits internally generated funding, increases dependence on external capital or partners, and makes future investment in the pipeline more vulnerable to financing constraints.

Neovacs SA (ALNEV) vs. iShares MSCI France ETF (EWQ)

-100%-75%-50%-25%0%25%FR:ALNEV-99.97%EWQ+2.46%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 124.97K
Dividend Yield
―
Average Volume (3M)
110.47K
Price to Earnings (P/E)
0.0
Beta (1Y)
1.78
Revenue Growth
-9.52%
EPS Growth
100.00%
Country
France
Employees
16
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Neovacs SA Business Overview & Revenue Model

Company Description

Based in Paris, France, Neovacs S.A. is a biotechnology firm established in 1993, dedicated to creating therapeutic vaccines for a range of conditions including autoimmune, inflammatory, allergic, and oncological diseases. The company leverages its p...

How the Company Makes Money

Neovacs’ business model is primarily biotechnology R&D-driven. The company would be expected to generate revenue through (1) out-licensing or co-development agreements for its Kinoid platform and/or individual drug candidates, typically structured wi...

Neovacs SA Financial Statement Overview

Summary

Highly volatile low revenue, persistent heavy losses, and ongoing cash burn typical of early-stage biotech, partially offset by low debt providing balance sheet stability.

Income Statement

15Very Negative

Balance Sheet

55Neutral

Cash Flow

20Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2023Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue228.77K161.78K533.41K366.35K1,11222.59K
Gross Profit-3.20M-4.52M-6.75M42.42K-6.26M-7.60M
EBITDA-5.24M-5.24M-8.45M-6.61M-3.61M-10.38M
Net Income-4.90M-4.90M-8.74M-32.91M-3.55M-11.84M
Balance Sheet
Total Assets22.14M22.14M47.53M22.07M49.28M48.55M
Cash, Cash Equivalents and Short-Term Investments571.79K571.79K887.09K435.45K6.76M33.09M
Total Debt537.20K537.20K650.59K230.37K1.20M1.03M
Total Liabilities4.10M4.10M3.71M4.01M5.05M4.65M
Stockholders Equity18.03M18.03M43.82M18.06M44.23M43.90M
Cash Flow
Free Cash Flow-5.04M-5.04M-2.12M-3.68M-4.60M-10.26M
Operating Cash Flow-5.03M-5.03M-1.91M-3.60M-4.45M-9.91M
Investing Cash Flow-446.17K-446.17K-11.08M1.45M-31.56M-18.81M
Financing Cash Flow5.62M5.62M6.79M1.70M9.99M51.75M

Neovacs SA Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

FR:ALNEV against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
FR:VLAFR:VLA51NeutralEUR 488.58M-2.85-152.15%―-27.19%-117.39%
FR:OSEFR:OSE49NeutralEUR 40.77M-1.02-96.73%―-96.25%-197.89%
FR:TNGFR:TNG48NeutralEUR 200.64M-4.31-29.36%―189.81%38.50%
FR:ABVXFR:ABVX44NeutralEUR 6.93B-16.79-85.88%―――
FR:ALNEVFR:ALNEV41NeutralEUR 124.97K0.00-26.52%―-9.52%100.00%
FR:DBVFR:DBV40UnderperformEUR 618.29M-3.61-121.83%――45.11%

* Healthcare Sector Average

Performance Comparison

-100%-50%0%50%FR:ALNEVFR:ABVXFR:DBVFR:TNGFR:VLAFR:OSEDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
FR:ALNEV and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
FR:ALNEVNeovacs SA0.07-263.93-99.97%
FR:ABVXAbivax SA76.90-21.80-22.09%
FR:DBVDbv Technologies SA (UK)1.87-0.53-22.00%
FR:TNGTransgene SA0.71-0.58-44.57%
FR:VLAValneva (0OB3)2.60-1.18-31.13%
FR:OSEOSE Immunotherapeutics1.68-3.74-68.99%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 14, 2026